The prophylactic effect of hydroxychloroquine on the severity of COVID-19 infection in an asymptomatic population: A randomized clinical trial
Social Determinants of Health,
Vol. 10 (2024),
1 January 2024
https://doi.org/10.22037/sdh.v10i1.43032
Abstract
Background: Laboratory and observational data suggest that hydroxychloroquine (HCQ) has biological activity against SARS-CoV-2, potentially permitting its use for disease prevention. This study aimed to evaluate the hydroxychloroquine effect as prophylaxis for SARS-CoV-2 infection.
Methods: In this double-blind randomized controlled trial, 1000 healthy people without any signs and symptoms of COVID-19 were randomly assigned in a 1:1 ratio to receive either 800 mg hydroxychloroquine or placebo (four 200 mg tablets in two divided doses on day 1 of the first week, followed by 200 mg (in a single dose) weekly for the next 6 weeks).
Results: Among 871 participants who remained and followed within 10 weeks 97(11.1%) became SARS-CoV-2 positive. there were statistically significant differences between infected or non-infected in the hydroxychloroquine (36 of 97 [37.1%]) and placebo (61 of 97 [62.9 %]) groups with a risk ratio of 2.1 (95% confidence interval (CI) 1.01 - 3.21; p = 0.005). The incidence of severe forms of COVID-19 ( hospitalized in the coronavirus ward or the ICU) was 2 of 97 (0.02 %) in participants who received a placebo compared to hydroxychloroquine. The proportion of non-infected people who received hydroxychloroquine prophylaxis was nearly twice higher than that of placebo users (1.87, 95% CI: 1.19 - 2.84, p = 0.05). There were no significant differences between the two groups regarding side effects (1.1% vs. 0.9%), and no severe adverse reactions were observed.
Conclusion: Pre-exposure therapy with hydroxychloroquine appears to prevent moderate and severe illness caused by COVID-19 in asymptomatic persons.
- Adverse Drug Reactions
- Hydroxychloroquine
- Pre-Exposure Prophylaxis
- SARS-CoV-2 COVID-19
How to Cite
References
Cao Y-c, Deng Q-x, Dai S-x. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel medicine and infectious disease. 2020;35:101647.
Shabani M, Totonchi M, Rezaeimirghaed O, Gachkar L, Hajiesmaeili M, Khoshkar A, et al. Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19. Pulm Pharmacol Ther. 2021;70:102069.
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clinical Infectious Diseases. 2023;76(3):e342-e9.
Huang F, Li Y, Leung EL-H, Liu X, Liu K, Wang Q, et al. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacological research. 2020;158:104929.
Panahi Y, Gorabi AM, Talaei S, Beiraghdar F, Akbarzadeh A, Tarhriz V, et al. An overview on the treatments and prevention against COVID-19. Virology Journal. 2023;20(1):1-29.
De Francia S, Chiara F, Allegra S. COVID-19 Prevention and Treatment. MDPI; 2023. p. 834.
Honein MA, Christie A, Rose DA, Brooks JT, Meaney-Delman D, Cohn A, et al. Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020. MMWR Morbidity and mortality weekly report. 2020;69(49):1860-7.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020;30(3):269-71.
Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. Journal of medicinal chemistry. 2006;49(9):2845-9.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-94.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;71(15):732-9.
Bhatt P, Patel V, Shah P, Parikh K. Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers. medRxiv. 2021:2021.08. 02.21260750.
Shabani M, Totonchi M, Rezaeimirghaed O, Gachkar L, Hajiesmaeili M, Khoshkar A, et al. Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19. Pulmonary Pharmacology & Therapeutics. 2021;70:102069.
Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. International journal of antimicrobial agents. 2020;56(3):106101.
Dhibar DP, Arora N, Kakkar A, Singla N, Mohindra R, Suri V, et al. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. International journal of antimicrobial agents. 2020;56(6):106224.
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medrxiv. 2020:2020.03. 22.20040758.
Jung S-Y, Kim M-S, Kim M-C, Choi S-H, Chung J-W, Choi ST. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. Clinical Microbiology and Infection. 2021;27(4):611-7.
Kashour Z, Kashour T, Gerberi D, Tleyjeh IM. Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID‐19 Patients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Clinical and translational science. 2021;14(3):1101-12.
Polo R, García-Albéniz X, Terán C, Morales M, Rial-Crestelo D, Garcinuño MA, et al. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers. Clinical Microbiology and Infection. 2023;29(1):85-93.
Bansal P, Goyal A, Cusick IV A, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Annals of medicine. 2021;53(1):117-34.
Naggie S, Milstone A, Castro M, Collins SP, Lakshmi S, Anderson DJ, et al. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ). International Journal of Infectious Diseases. 2023;129:40-8.
Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, et al. Hydroxychloroquine as prophylaxis for COVID-19: a review. Frontiers in pharmacology. 2020;11:605185.
Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. Journal of critical care. 2020;59:176-90.
Smit M, Marinosci A, Agoritsas T, Calmy A. Prophylaxis for COVID-19: a systematic review. Clinical microbiology and infection. 2021;27(4):532-7.
Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-40.
Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;101:283-9.
Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E, et al. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. International journal of antimicrobial agents. 2020;56(4):106144.
Sen S, Werner A, Shekhar A. Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy. Drugs & therapy perspectives : for rational drug selection and use. 2020:1-2.
Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. The New England journal of medicine. 2020;383(6):517-25.
Cohen MS. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. The New England journal of medicine. 2020;383(6):585-6.
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology. 2021;3(1):e19-e27.
Kloc M, Ghobrial RM, Kubiak JZ. The Role of Genetic Sex and Mitochondria in Response to COVID-19 Infection. International archives of allergy and immunology. 2020;181(8):629-34.
Ruggieri A, Anticoli S, D'Ambrosio A, Giordani L, Viora M. The influence of sex and gender on immunity, infection and vaccination. Annali dell'Istituto superiore di sanita. 2016;52(2):198-204.
Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biology of sex differences. 2020;11(1):53.
Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? International journal of epidemiology. 2020;49(3):717-26.
- Abstract Viewed: 2588 times
- PDF Downloaded: 41 times